secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2023-03-23T23:59:59+00:00
Accession:  0001372514-23-000051
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora Pharmaceuticals reports FY2022 net loss of $13.6M; clinical milestones on track for 2023
--------------------------------------------------------------------------------

- Net loss of $13.6M for FY2022, compared to $13.8M in FY2021; Q4 net loss $2.5M.
- Cash and equivalents $6.0M at Dec 31, 2022, plus $1.4M in R&D tax receivables.
- KIO-301 Phase 1b ABACUS trial enrollment ongoing; initial results at ARVO April 2023, topline by year-end.
- KIO-201 Phase 2 PCED study topline results at ARVO; mean defect size reduction 90% (p<0.003).
- KIO-101 Phase 2 trial initiation planned for Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251423000051/0001372514-23-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251423000051/kprx-20230323.htm
  HTML page:      https://secwatch.observer/filing/0001372514-23-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer